Article
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2020
Smyth Lillian M, Tamura Kenji, Oliveira Mafalda, Ciruelos Eva M, Mayer Ingrid A, Sablin Marie-Paule, Biganzoli Laura, Ambrose Helen J, Ashton Jack, Barnicle Alan, Cashell Des D, Corcoran Claire, de Bruin Elza C, Foxley Andrew, Hauser Joana, Lindemann Justin P O, Maudsley Rhiannon, McEwen Robert, Moschetta Michele, Pass Martin, Rowlands Vicky, Schiavon Gaia, Banerji Udai, Scaltriti Maurizio, Taylor Barry S, Chandarlapaty Sarat, Baselga José, Hyman David M
Abstract excerpt
PURPOSE: The activating mutation AKT1 E17K occurs in approximately 7% of estrogen receptor-positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study (NCT01226316), tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy or combined with fulvestrant in expansion cohorts of patients with AKT1 E17K-mutant ER+ MBC. PATIENTS AND METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.